Motley Fool  Oct 14  Comment 
Even though the market managed to gain ground, these stocks fell. Find out why.
Motley Fool  Oct 14  Comment 
Worry over mounting political scrutiny of its pricing of Iclusig led investors to head for the exits today.
Clusterstock  Oct 14  Comment 
Senator Bernie Sanders just called out Ariad Pharmaceuticals over the price of its leukemia drug, and the company's stock dropped fast. Ariad, which makes a drug called Iclusig, has raised the price of the drug four times this year, The Street...
Motley Fool  Oct 11  Comment 
Buyout rumors sparked a rally in this cancer treatment specialist last month.
Motley Fool  Oct 9  Comment 
Cancer drug development is costly and fraught with failure, but these three companies have successfully navigated clinical trials and as a result, each has a chance at winning FDA approval of their drugs in 2017.
FiercePharma  Oct 7  Comment 
UPDATED: What's the next pricing uproar? Ariad, Novum and Lannett could be candidates tracystaton Fri, 10/07/2016 - 09:59
Benzinga  Oct 5  Comment 
Drug pricing has been one of the central issues of the 2016 presidential campaign. There is currently a whirlwind of negative public sentiment swirling around controversial pricing practices of companies like Valeant Pharmaceuticals Intl Inc...
Benzinga  Oct 5  Comment 
SunTrust Robinson Humphrey sees potential upside of 65 percent in Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) given clinical catalysts and the company could be a takeover target. Ariad's lead product Iclusig is a potent chronic myeloid leukemia...


Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki